A new effort is underway to establish clear regulations for hemp-derived CBD oil products. Here’s a simplified breakdown of the key points:
Bill Reintroduced for FDA Regulation
A bipartisan group of U.S. Senators—Ron Wyden, Rand Paul, and Jeff Merkley—have reintroduced the Hemp Access and Consumer Safety Act. This bill aims to provide a clear regulatory framework for the FDA to manage hemp-derived CBD as dietary supplements or food and beverage additives.
Key Aspects of the Bill:
- Legal Use: Allows hemp-derived CBD in dietary supplements, foods, and beverages.
- Consumer Safety: Ensures manufacturers follow all federal regulations.
- Proper Labeling: Mandates accurate product labeling.
Senator Wyden emphasized the need for this legislation, stating that despite being legal for almost five years, hemp and CBD still exist in a regulatory gray area, which can be risky for consumers and hinder producers. The bill is supported by various industry groups, including the U.S. Hemp Roundtable and the American Herbal Products Association.
Congressional Hearing on FDA Inaction
On July 27, a hearing titled “Hemp in the Modern World: The Years-long Wait for FDA Action” took place before the House Oversight and Accountability Committee’s Subcommittee on Health Care and Financial Services. Experts discussed the impact of the FDA’s failure to establish a regulatory pathway for hemp products like CBD.
Key Points from the Hearing:
- Consumer Safety: The lack of regulations poses health risks.
- Industry Disruption: Hemp farmers and businesses face significant challenges due to regulatory uncertainty.
- Regulatory Need: Both witnesses and committee members agreed on the urgent need for a regulatory framework for hemp-derived cannabinoids.
Jonathan Miller, General Counsel of the U.S. Hemp Roundtable, highlighted the adverse effects of the FDA’s inaction, including consumer safety issues and market instability.
Addressing Safety Concerns
The FDA has expressed safety concerns about CBD, especially regarding long-term consumption. The Natural Products Association criticized the FDA for using drug standards to evaluate CBD, arguing that this approach is misleading and hinders regulatory progress. Witnesses at the hearing called for the FDA to use existing data to establish a safety assessment for CBD similar to other food and supplement ingredients.
Intoxicating Cannabinoids Issue
An important safety issue discussed was the proliferation of products containing intoxicating cannabinoids like delta-8 THC, which are sold unregulated and sometimes to minors. Witnesses stressed the need for strict regulations to ensure these products are safe and kept out of the hands of children.
Jonathan Miller noted that while these products can benefit consumers when manufactured correctly, they must be strictly regulated.
The reintroduction of the Hemp Access and Consumer Safety Act and the recent congressional hearing mark significant steps toward establishing a clear regulatory framework for hemp-derived CBD, aiming to ensure consumer safety and support the hemp industry’s growth.
